Why is the Polynovo share price on ice today?

Polynovo shares aren't trading today. Let's take a look at what's going on.

| More on:
A man sits in a chair hunched over a laptop and covered head to toe in frozen icicles to represent Envirosuite's trading halt

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The All Ordinaries Index (ASX: XAO) is enjoying some time in the sun today. At the time of writing, the All Ords has gained a healthy 0.5%, putting it back over 7,370 points. But one ASX All Ords share is missing out on the party today. That would be the Polynovo Ltd (ASX: PNV) share price.

Polynovo shares aren't trading today. The company finished at $2.09 a share yesterday afternoon, a level it will be staying at for a while. So what's going on with this ASX healthcare share that has it barred from trading?

Well, Polynovo released an ASX announcement this morning before market open that tells us some of what is going on.

Polynovo share price frozen amid capital raise

So yes, Polynovo shares are suspended from trading at the request of the company. The purpose of this suspension is to allow Polynovo to conduct a capital raise.

This will be in three stages. The first is a $30 million institutional share placement for institutional investors. The second is a $17 million share purchase plan, available for retail investors. The third is a $3 million share placement available only to certain directors of the company.

All up, the $47 million that Polynovo hopes to raise will:

Accelerate growth in the US and the rest of the world, including the newest markets in Canada, India and Hong Kong… This will also include the construction of a new manufacturing and R&D facility, next to the existing [Melbourne] factory, to satisfy the significant increase in demand for NovoSorb.

Eligible shareholders will have the option to apply for up to $30,000 in new Polynovo shares at a price of $1.90 each, a 9.1% discount to the company's last traded share price of $2.09.

For retail investors, the new shares issued under the placement will start trading on 21 December next month. Polynovo expects its shares to resume ASX trading tomorrow.

The Polynovo share price is up almost 34% year to date in 2022 thus far. It's also up more than 130% since May.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended POLYNOVO FPO. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A young woman holds an open book over her head with a round mouthed expression as if to say oops as she looks at her computer screen in a home office setting with a plant on the desk and shelves of books in the background.
Healthcare Shares

This ASX All Ords share is diving 18% as inflation pain draws blood

This healthcare company delivered a trading update at its annual general meeting today.

Read more »

Shot of a young scientist using a digital tablet while working in a lab.
Healthcare Shares

Up 427% this year, why today is a big day for Mesoblast shares

Why is everyone talking about Mesoblast shares on Friday?

Read more »

A man holds his hand under his chin as he concentrates on his laptop screen and reads about the ANZ share price
Healthcare Shares

Is this beaten-down ASX healthcare share a bargain buy now?

One expert has given their view on this stock.

Read more »

drug capsule opening up to reveal dollar signs signifying rising asx share price
Healthcare Shares

3 ASX healthcare shares going gangbusters on Thursday

Investors are sending these ASX healthcare stocks soaring today. But why?

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Is it time to cash in on Sigma shares?

Shares have extended after the Chemist Warehouse merger.

Read more »

Person holding Australian dollar notes, symbolising dividends.
Healthcare Shares

Buy this ASX 200 share that is swimming in cash

Bell Potter sees potentially big returns on offer from this cashed-up stock.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Are CSL shares a buy after the biotech's FY25 forecasts?

Brokers continue to weigh in.

Read more »

Female pharmacist smiles with a digital tablet.
Healthcare Shares

Are Wesfarmers or Sigma shares a better buy in the pharmacy arena?

These two stocks are both leaders in the industry.

Read more »